Clinical Trial Update: A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease [Phase 3]

View source ↗

Summary

Phase 3 dose-ranging trial of ferric citrate (KRX-0502) in end-stage renal disease patients with hyperphosphatemia. Results from the study have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hyperphosphatemia

Drugs mentioned

• Ferric citrate (ferric citrate)

Snippet

Sponsor: Keryx Biopharmaceuticals | Conditions: Hyperphosphatemia, End-Stage Renal Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-12-04